According to studies, FOXD2-AS1 is up-regulated in a variety of cancers, including gastric cancer, bladder cancer, nasopharyngeal cancer, lung cancer, esophageal cancer, liver cancer, thyroid cancer, colorectal cancer, and skin cancer, and promotes cancer cell proliferation, migration, and invasion, and is negatively correlated with prognosis [27]. This evidence concerns the gene FOXD2 and urinary bladder carcinoma.